

Jon Stoessl

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7075033/jon-stoessl-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

261 papers	18,979 citations	62 h-index	133 g-index
290 ext. papers	21,397 ext. citations	7.9 avg, IF	6.3 L-index

#	Paper	IF	Citations
261	Cortical morphology predicts placebo response in multiple sclerosis.. <i>Scientific Reports</i> , 2022 , 12, 732	4.9	
260	Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies. <i>Movement Disorders</i> , 2021 , 36, 1781-1791	7	5
259	Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia. <i>Movement Disorders</i> , 2021 , 36, 389-397	7	6
258	Weeding through the haze: a survey on cannabis use among people living with Parkinson's disease in the US. <i>Npj Parkinsons Disease</i> , 2021 , 7, 21	9.7	2
257	Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review. <i>JAMA Neurology</i> , 2021 , 78, 1262-1272	17.2	10
256	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinsons Disease</i> , 2020 , 10, 875-891	5.3	28
255	Deception and the ethics of placebo. <i>International Review of Neurobiology</i> , 2020 , 153, 147-163	4.4	0
254	Immunotherapy for Parkinson's disease: stay tuned. <i>Lancet Neurology, The</i> , 2020 , 19, 561-562	24.1	
253	Novel data-driven, equation-free method captures spatio-temporal patterns of neurodegeneration in Parkinson's disease: Application of dynamic mode decomposition to PET. <i>NeuroImage: Clinical</i> , 2020 , 25, 102150	5.3	0
252	Optical coherence tomography of patients with Parkinson's disease and progressive supranuclear palsy. <i>Clinical Neurology and Neurosurgery</i> , 2020 , 189, 105635	2	6
251	COVID-19 and selective vulnerability to Parkinson's disease. <i>Lancet Neurology, The</i> , 2020 , 19, 719	24.1	26
250	Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals?. <i>Movement Disorders</i> , 2019 , 34, 1406-1422	7	37
249	Dopamine replacement remediates risk aversion in Parkinson's disease in a value-independent manner. <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 189-194	3.6	0
248	Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson's disease induced presynaptic alterations. <i>NeuroImage: Clinical</i> , 2019 , 23, 101856	5.3	14
247	Occult central pontine myelinolysis post liver transplant: A consequence of pre-transplant hyponatremia. <i>Annals of Hepatology</i> , 2019 , 18, 651-654	3.1	1
246	Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2019 , 9, 301-313	5.3	75
245	Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease. <i>Movement Disorders</i> , 2019 , 34, 1891-1900	7	41

244	Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. <i>Brain</i> , 2019 , 142, 512-525	11.2	142
243	Movement Disorders Journal: Yesterday, Today, Tomorrow, and Always. <i>Movement Disorders</i> , 2019 , 34, 1814-1816	7	1
242	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. <i>Journal of Parkinson's Disease</i> , 2019 , 9, 31-61	5.3	33
241	The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study. <i>Lancet Neurology</i> , 2018 , 17, 309-316	24.1	35
240	Dyskinesias and levodopa therapy: why wait?. <i>Journal of Neural Transmission</i> , 2018 , 125, 1119-1130	4.3	9
239	PBB3 binding in a patient with corticobasal syndrome. <i>Movement Disorders</i> , 2018 , 33, 1359-1360	7	5
238	Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach. <i>Current Medical Research and Opinion</i> , 2018 , 34, 2063-2073	2.5	82
237	Conclusions. <i>Movement Disorders</i> , 2018 , 33, 701	7	
236	Data-driven, voxel-based analysis of brain PET images: Application of PCA and LASSO methods to visualize and quantify patterns of neurodegeneration. <i>PLoS ONE</i> , 2018 , 13, e0206607	3.7	8
235	Operationalizing Neuroimaging for Disorders of Consciousness in the Canadian Context. <i>Canadian Journal of Neurological Sciences</i> , 2018 , 45, 633-635	1	
234	Win-Concurrent Sensory Cues Can Promote Riskier Choice. <i>Journal of Neuroscience</i> , 2018 , 38, 10362-10370	10.6	14
233	Habitual exercisers versus sedentary subjects with Parkinson's Disease: Multimodal PET and fMRI study. <i>Movement Disorders</i> , 2018 , 33, 1945-1950	7	18
232	PET Molecular Imaging in Familial Parkinson's Disease. <i>International Review of Neurobiology</i> , 2018 , 142, 177-223	4.4	4
231	Neurobiology of placebo effect in Parkinson's disease: What we have learned and where we are going. <i>Movement Disorders</i> , 2018 , 33, 1213-1227	7	20
230	Investigation of serotonergic Parkinson's disease-related covariance pattern using [C]-DASB/PET. <i>NeuroImage: Clinical</i> , 2018 , 19, 652-660	5.3	18
229	Gender differences in Parkinson's disease depression. <i>Parkinsonism and Related Disorders</i> , 2017 , 36, 93-97	3.6	21
228	Molecular imaging to track Parkinson's disease and atypical parkinsonisms: New imaging frontiers. <i>Movement Disorders</i> , 2017 , 32, 181-192	7	56
227	Glucose utilization: still in the synapse. <i>Nature Neuroscience</i> , 2017 , 20, 382-384	25.5	35

226	Reversible Parkinsonism and Rapidly Progressive Dementia Due to Dural Arteriovenous Fistula: Case Series and Literature Review. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 607-611	2.2	7
225	Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. <i>Annals of Neurology</i> , 2017 , 81, 46-57	9.4	54
224	PBB3 imaging in Parkinsonian disorders: Evidence for binding to tau and other proteins. <i>Movement Disorders</i> , 2017 , 32, 1016-1024	7	46
223	The underlying mechanism of prodromal PD: insights from the parasympathetic nervous system and the olfactory system. <i>Translational Neurodegeneration</i> , 2017 , 6, 4	10.3	14
222	Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies. <i>Lancet Neurology</i> , <i>The</i> , 2017 , 16, 351-359	24.1	64
221	Challenges and unfulfilled promises in Parkinson's disease. <i>Lancet Neurology</i> , <i>The</i> , 2017 , 16, 866-867	24.1	4
220	Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. <i>Movement Disorders</i> , 2017 , 32, 1264-1310	7	375
219	DNAJC12 and dopa-responsive nonprogressive parkinsonism. <i>Annals of Neurology</i> , 2017 , 82, 640-646	9.4	38
218	Homozygous alpha-synuclein p.A53V in familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2017 , 57, 248.e7-248.e12	5.6	51
217	Movement disorders. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2016 , 136, 957-69	3	10
216	Optimizing diagnosis in Parkinson's disease: Radionuclide imaging. <i>Parkinsonism and Related Disorders</i> , 2016 , 22 Suppl 1, S47-51	3.6	18
215	Comment: Increased D3 binding-A substrate for levodopa-induced dyskinesias?. <i>Neurology</i> , 2016 , 86, 228	6.5	2
214	The role of biomarkers and imaging in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2016 , 16, 187-203	4.3	9
213	Raul de la Fuente-Fernandez, February 22, 1959-May 11, 2016. <i>Movement Disorders</i> , 2016 , 31, 1144-5	7	
212	A scan without evidence is not evidence of absence: Scans without evidence of dopaminergic deficit in a symptomatic leucine-rich repeat kinase 2 mutation carrier. <i>Movement Disorders</i> , 2016 , 31, 405-9	7	12
211	Ethical and Clinical Considerations at the Intersection of Functional Neuroimaging and Disorders of Consciousness. <i>Cambridge Quarterly of Healthcare Ethics</i> , 2016 , 25, 613-22	0.9	7
210	Is Axonal Degeneration a Key Early Event in Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , 2016 , 6, 703-707	5.3	30
209	Salivary gland biopsy for diagnosis of Parkinson's disease?. <i>Lancet Neurology</i> , <i>The</i> , 2016 , 15, 654-656	24.1	5

208	DCTN1 p.K56R in progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2016 , 28, 56-61	3.6	24
207	Reply to letter to the editor: Is there anything more to learn from SWEDD?. <i>Movement Disorders</i> , 2016 , 31, 1426-8	7	
206	Imaging in Parkinson's disease: time to look below the neck. <i>Brain</i> , 2015 , 138, 512-4	11.2	2
205	DNAJC13 genetic variants in parkinsonism. <i>Movement Disorders</i> , 2015 , 30, 273-8	7	32
204	Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. <i>Progress in Neurobiology</i> , 2015 , 132, 96-168	10.9	282
203	Phosphorylated α -synuclein in Parkinson's disease: correlation depends on disease severity. <i>Acta Neuropathologica Communications</i> , 2015 , 3, 7	7.3	53
202	Central pharmacokinetics of levodopa: Lessons from imaging studies. <i>Movement Disorders</i> , 2015 , 30, 73-9	7	8
201	Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. <i>JAMA Neurology</i> , 2015 , 72, 100-5	17.2	191
200	Canadian perspectives on the clinical actionability of neuroimaging in disorders of consciousness. <i>Canadian Journal of Neurological Sciences</i> , 2015 , 42, 96-105	1	6
199	Developments in neuroimaging: positron emission tomography. <i>Parkinsonism and Related Disorders</i> , 2014 , 20 Suppl 1, S180-3	3.6	8
198	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 67-69	2.2	13
197	SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. <i>Neurogenetics</i> , 2014 , 15, 23-30	3	49
196	DNAJC13 mutations in Parkinson disease. <i>Human Molecular Genetics</i> , 2014 , 23, 1794-801	5.6	209
195	A familial form of parkinsonism, dementia, and motor neuron disease: a longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1129-34	3.6	6
194	The effects of exercise on cognition in Parkinson's disease: a systematic review. <i>Translational Neurodegeneration</i> , 2014 , 3, 5	10.3	114
193	Imaging insights into basal ganglia function, Parkinson's disease, and dystonia. <i>Lancet, The</i> , 2014 , 384, 532-44	40	104
192	Imaging in multiple system atrophy. <i>Neurology and Clinical Neuroscience</i> , 2014 , 2, 178-187	0.3	6
191	Clinical, positron emission tomography, and pathological studies of DNAJC13 p.N855S Parkinsonism. <i>Movement Disorders</i> , 2014 , 29, 1684-7	7	15

190 Imaging of Dopamine and Serotonin Receptors and Transporters **2014**, 241-264

189 In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers. *Movement Disorders*, **2014**, 29, 1197-201 7 12

188 Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging. *Journal of Parkinsons Disease*, **2014**, 4, 483-98 5.3 27

187 Gene therapy for Parkinson's disease: a step closer?. *Lancet, The*, **2014**, 383, 1107-9 40 15

186 A brain network response to sham surgery. *Journal of Clinical Investigation*, **2014**, 124, 3285-8 15.9 1

185 Insights into LRRK2-Mutation Related PD from PET Imaging Studies **2014**, 123-124

184 Measurements of Dopaminergic Function in the Rat Brain Using [18F]FDOPA PET and Microdialysis **2014**, 161

183 Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions. *Pharmacology & Therapeutics*, **2013**, 140, 306-18 13.9 43

182 Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. *Parkinsonism and Related Disorders*, **2013**, 19, 869-77 3.6 45

181 Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude. *Neuropsychologia*, **2013**, 51, 2679-89 3.2 8

180 Novel spatial analysis method for PET images using 3D moment invariants: applications to Parkinson's disease. *NeuroImage*, **2013**, 68, 11-21 7.9 15

179 Measuring dopaminergic function in the 6-OHDA-lesioned rat: a comparison of PET and microdialysis. *EJNMMI Research*, **2013**, 3, 69 3.6 14

178 Biomarkers for trials of neuroprotection in Parkinson's disease. *Movement Disorders*, **2013**, 28, 71-85 7 18

177 Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. *Neurology*, **2013**, 81, 1322-31 6.5 45

176 Neurology in Canada: history of the Canadian Neurological Society. *Neurology*, **2013**, 80, 406-8 6.5 2

175 Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. *Movement Disorders*, **2013**, 28, 811-3 7 433

174 In-vivo measurement of LDOPA uptake, dopamine reserve and turnover in the rat brain using [18F]FDOPA PET. *Journal of Cerebral Blood Flow and Metabolism*, **2013**, 33, 59-66 7.3 21

173 The nature of progression in Parkinson's disease: an application of non-linear, multivariate, longitudinal random effects modelling. *PLoS ONE*, **2013**, 8, e76595 3.7 23

172	Neuroimaging of Sleep and Sleep Disorders 2013 ,		3
171	Neuroimaging in the early diagnosis of neurodegenerative disease. <i>Translational Neurodegeneration</i> , 2012 , 1, 5	10.3	25
170	Neuroimaging in Parkinson's disease: from pathology to diagnosis. <i>Parkinsonism and Related Disorders</i> , 2012 , 18 Suppl 1, S55-9	3.6	32
169	Imaging striatal dopaminergic function in phospholipase A2 group VI-related parkinsonism. <i>Movement Disorders</i> , 2012 , 27, 1698-9	7	12
168	DJ-1 and BDNF in LRRK2 CSF do not correlate with striatal dopaminergic function. <i>Neurobiology of Aging</i> , 2012 , 33, 836.e5-7	5.6	31
167	Imaging neural correlates of mild cognitive impairment in Parkinson's disease. <i>Lancet Neurology, The</i> , 2012 , 11, 653-5	24.1	11
166	Creation of an open-access, mutation-defined fibroblast resource for neurological disease research. <i>PLoS ONE</i> , 2012 , 7, e43099	3.7	35
165	Neuroimaging: current role in detecting pre-motor Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 634-43	7	21
164	Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites. <i>Neurology</i> , 2012 , 78, 649-57	6.5	69
163	Cerebrospinal fluid amyloid β and tau in LRRK2 mutation carriers. <i>Neurology</i> , 2012 , 78, 55-61	6.5	37
162	Liquid Xenon Detectors for Positron Emission Tomography. <i>Journal of Physics: Conference Series</i> , 2011 , 312, 062006	0.3	1
161	Movement disorders: new insights into Parkinson's disease. <i>Lancet Neurology, The</i> , 2011 , 10, 5-7	24.1	2
160	Advances in imaging in Parkinson's disease. <i>Lancet Neurology, The</i> , 2011 , 10, 987-1001	24.1	82
159	Functional Imaging Studies in Parkinson's Disease: The Non-Dopaminergic Systems 2011 , 105-110		
158	Neuroimaging in Parkinson's disease. <i>Neurotherapeutics</i> , 2011 , 8, 72-81	6.4	49
157	Milestones in neuroimaging. <i>Movement Disorders</i> , 2011 , 26, 868-978	7	7
156	Age-specific progression of nigrostriatal dysfunction in Parkinson's disease. <i>Annals of Neurology</i> , 2011 , 69, 803-10	9.4	168
155	Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease. <i>Brain</i> , 2011 , 134, 3290-8	11.2	102

154	A family with Parkinsonism, essential tremor, restless legs syndrome, and depression. <i>Neurology</i> , 2011 , 76, 1623-30	6.5	25
153	Effects of expectation on placebo-induced dopamine release in Parkinson disease. <i>Archives of General Psychiatry</i> , 2010 , 67, 857-65		207
152	Effect of electroconvulsive therapy on brain 5-HT(2) receptors in major depression. <i>British Journal of Psychiatry</i> , 2010 , 196, 474-9	5.4	61
151	Parkin and Parkinson's disease: differentiated by non-dopaminergic dysfunction?. <i>Experimental Neurology</i> , 2010 , 225, 48-50	5.7	
150	Imaging the nigrostriatal system to monitor disease progression and treatment-induced complications. <i>Progress in Brain Research</i> , 2010 , 184, 177-92	2.9	16
149	Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. <i>Movement Disorders</i> , 2010 , 25, 2717-23	7	82
148	Dopamine transporter PET in normal aging: dopamine transporter decline and its possible role in preservation of motor function. <i>Synapse</i> , 2010 , 64, 146-51	2.4	36
147	Response to heat pain stimulation in idiopathic Parkinson's disease. <i>Pain Medicine</i> , 2010 , 11, 834-40	2.8	27
146	Radionuclide scanning to diagnose Parkinson disease: is it cost-effective?. <i>Nature Clinical Practice Neurology</i> , 2009 , 5, 10-1		6
145	PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. <i>Neurology</i> , 2009 , 72, 1211-6	6.5	92
144	Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. <i>Brain</i> , 2009 , 132, 2970-9	11.2	185
143	Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double blind video-based analysis. <i>Movement Disorders</i> , 2009 , 24, 336-43	7	68
142	Visualizing vesicular dopamine dynamics in Parkinson's disease. <i>Synapse</i> , 2009 , 63, 713-6	2.4	42
141	DCTN1 mutations in Perry syndrome. <i>Nature Genetics</i> , 2009 , 41, 163-5	36.3	239
140	Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. <i>Journal of Neurochemistry</i> , 2009 , 109, 85-92	6	42
139	Pallidonigral TDP-43 pathology in Perry syndrome. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 281-6	3.6	72
138	Familial parkinsonism: study of original Sagami-hara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 300-6	3.6	78
137	Genetic factors influencing age at onset in LRRK2-linked Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 539-41	3.6	26

136	Functional imaging studies of non-motoric manifestations of Parkinson's Disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15 Suppl 3, S13-6	3.6	16
135	Safety and tolerability of intraputamin delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. <i>Lancet Neurology, The</i> , 2008 , 7, 400-8	24.1	450
134	Functional imaging in Parkinson disease. <i>Neurology</i> , 2008 , 70, 1478-88	6.5	61
133	Potential therapeutic targets for Parkinson's disease. <i>Expert Opinion on Therapeutic Targets</i> , 2008 , 12, 425-36	6.4	11
132	Progression of dopaminergic dysfunction in a LRRK2 kindred: a multitracer PET study. <i>Neurology</i> , 2008 , 71, 1790-5	6.5	95
131	Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease. <i>Annals of Neurology</i> , 2008 , 63, 388-94	9.4	60
130	LRRK2 (Leucine-Rich Repeat Kinase 2) Gene on PARK8 Locus in Families with Parkinsonism 2008 , 75-89		
129	Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. <i>Annals of Neurology</i> , 2007 , 62, 468-74	9.4	106
128	Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 359-65	7	42
127	Joubert syndrome surviving to adulthood associated with a progressive movement disorder. <i>Movement Disorders</i> , 2007 , 22, 262-5	7	2
126	Is there seasonal variation in risk of Parkinson's disease?. <i>Movement Disorders</i> , 2007 , 22, 1097-101	7	10
125	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007 , 22, 2409-17	7	174
124	Understanding the placebo effect: contributions from neuroimaging. <i>Molecular Imaging and Biology</i> , 2007 , 9, 176-85	3.8	65
123	Gene therapy for Parkinson's disease: early data. <i>Lancet, The</i> , 2007 , 369, 2056-8	40	13
122	Positron emission tomography in premotor Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007 , 13 Suppl 3, S421-4	3.6	35
121	GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology, The</i> , 2006 , 5, 200-2	24.1	29
120	Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies. <i>Movement Disorders</i> , 2006 , 21, 970-5	7	12
119	Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation. <i>Movement Disorders</i> , 2006 , 21, 1457-61	7	88

118	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Annals of Neurology</i> , 2006 , 59, 459-66	9.4	785
117	Age-related differences in levodopa dynamics in Parkinson's: implications for motor complications. <i>Brain</i> , 2006 , 129, 1050-8	11.2	71
116	Autosomal dominant dystonia-plus with cerebral calcifications. <i>Neurology</i> , 2006 , 67, 620-5	6.5	31
115	Genetic heterogeneity in paroxysmal nonkinesigenic dyskinesia. <i>Neurology</i> , 2006 , 66, 1588-90	6.5	58
114	Parkinson's disease: in vivo assessment of disease progression using positron emission tomography. <i>Molecular Brain Research</i> , 2005 , 134, 24-33		35
113	The placebo response as a reward mechanism. <i>Seminars in Pain Medicine</i> , 2005 , 3, 37-42		17
112	PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. <i>Brain</i> , 2005 , 128, 2777-85	11.2	208
111	Progress in clinical neurosciences: a forum on the early management of Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 2005 , 32, 277-86	1	3
110	Treatment for the progression of Parkinson's disease. <i>Lancet Neurology</i> , 2005 , 4, 206	24.1	5
109	Positron emission tomography after fetal transplantation in Huntington's disease. <i>Annals of Neurology</i> , 2005 , 58, 331-7	9.4	50
108	On the Use of Clusters to Determine Environmental Influence on DiseaseReply. <i>Archives of Neurology</i> , 2005 , 62, 331		
107	Positron Emission Tomography in Parkinson's Disease 2005 , 25-35		2
106	Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. <i>Brain</i> , 2004 , 127, 888-99	11.2	98
105	Clustering of Parkinson disease: shared cause or coincidence?. <i>Archives of Neurology</i> , 2004 , 61, 1057-60		23
104	Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004 , 24, 869-76	7.3	73
103	The biochemical bases of the placebo effect. <i>Science and Engineering Ethics</i> , 2004 , 10, 143-50	3.1	30
102	Tremor induced by thalamic deep brain stimulation in patients with complex regional facial pain. <i>Movement Disorders</i> , 2004 , 19, 933-6	7	20
101	Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). <i>Movement Disorders</i> , 2004 , 19, 622-9	7	112

100	Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. <i>Brain</i> , 2004 , 127, 2747-54	11.2	307
99	. <i>IEEE Transactions on Nuclear Science</i> , 2004 , 51, 205-211	1.7	3
98	Placebo mechanisms and reward circuitry: clues from Parkinson's disease. <i>Biological Psychiatry</i> , 2004 , 56, 67-71	7.9	107
97	Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. <i>Neuron</i> , 2004 , 44, 601-7	13.9	2228
96	The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. <i>American Journal of Human Genetics</i> , 2004 , 74, 11-9	11	169
95	Willing oneself better on placebo--effective in its own right. <i>Lancet, The</i> , 2004 , 364, 227-8	40	20
94	Lack of regional selectivity during the progression of Parkinson disease: implications for pathogenesis. <i>Archives of Neurology</i> , 2004 , 61, 1920-5		41
93	[11C]DTBZ-PET correlates of levodopa responses in asymmetric Parkinson's disease. <i>Brain</i> , 2003 , 126, 2648-55	11.2	57
92	Etiology of Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 2003 , 30 Suppl 1, S10-8	1	29
91	Neural transplantation for the treatment of Parkinson's disease. <i>Lancet Neurology, The</i> , 2003 , 2, 437-45	24.1	278
90	Leg muscle strength is reduced in Parkinson's disease and relates to the ability to rise from a chair. <i>Movement Disorders</i> , 2003 , 18, 157-62	7	118
89	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003 , 54, 93-101	9.4	691
88	A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. <i>Annals of Neurology</i> , 2003 , 54, 403-14	9.4	1206
87	Age and severity of nigrostriatal damage at onset of Parkinson's disease. <i>Synapse</i> , 2003 , 47, 152-8	2.4	32
86	VMAT2 binding is elevated in dopa-responsive dystonia: visualizing empty vesicles by PET. <i>Synapse</i> , 2003 , 49, 20-8	2.4	61
85	Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. <i>Experimental Neurology</i> , 2003 , 184 Suppl 1, S68-79	5.7	133
84	Agonizing over dopaminergic replacement therapy--lessons from animal models of Parkinson's disease. <i>Experimental Neurology</i> , 2003 , 183, 1-3	5.7	4
83	Effects of oligonucleotide antisense to dopamine D3 receptor mRNA in a rodent model of behavioural sensitization to levodopa. <i>Neuroscience</i> , 2003 , 116, 307-14	3.9	41

82	Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia. <i>Neuroscience</i> , 2003 , 119, 547-55	3.9	14
81	The placebo effect in neurological disorders. <i>Lancet Neurology, The</i> , 2002 , 1, 85-91	24.1	142
80	[18F]-Dopa positron emission tomography imaging in early-stage, non-parkin juvenile parkinsonism. <i>Movement Disorders</i> , 2002 , 17, 789-94	7	11
79	Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2002 , 22, 232-9	7.3	101
78	The biochemical bases for reward. Implications for the placebo effect. <i>Evaluation and the Health Professions</i> , 2002 , 25, 387-98	2.5	48
77	PET study of [(18F)]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. <i>American Journal of Psychiatry</i> , 2002 , 159, 768-74	11.9	105
76	Bilateral human fetal striatal transplantation in Huntington's disease. <i>Neurology</i> , 2002 , 58, 687-95	6.5	208
75	SCA-2 presenting as parkinsonism in an Alberta family: clinical, genetic, and PET findings. <i>Neurology</i> , 2002 , 59, 1625-7	6.5	103
74	Parkinson's disease: imaging update. <i>Current Opinion in Neurology</i> , 2002 , 15, 477-82	7.1	20
73	Rett syndrome: investigation of nine patients, including PET scan. <i>Canadian Journal of Neurological Sciences</i> , 2002 , 29, 345-57	1	31
72	PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. <i>American Journal of Psychiatry</i> , 2002 , 159, 1718-23	11.9	73
71	Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats. <i>Neuroscience</i> , 2002 , 112, 261-6	3.9	10
70	Blockade of nigral and pallidal opioid receptors suppresses vacuous chewing movements in a rodent model of tardive dyskinesia. <i>Neuroscience</i> , 2002 , 112, 851-9	3.9	21
69	The placebo effect in Parkinson's disease. <i>Trends in Neurosciences</i> , 2002 , 25, 302-6	13.3	123
68	Dopamine release in human ventral striatum and expectation of reward. <i>Behavioural Brain Research</i> , 2002 , 136, 359-63	3.4	275
67	Pharmacodynamic modeling of oral levodopa in Parkinson's disease. <i>Annals of Neurology</i> , 2001 , 50, 687-9	9.4	2
66	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. <i>Annals of Neurology</i> , 2001 , 49, 298-303	9.4	179
65	Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2001 , 21, 1151-9	7.3	46

64	Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. <i>Science</i> , 2001 , 293, 1164-6	33.3	732
63	Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal dementia with parkinsonism linked to chromosome 17 and point mutation in tau gene). <i>Parkinsonism and Related Disorders</i> , 2001 , 7, 81-88	3.6	24
62	Alternating two finger tapping with contralateral activation is an objective measure of clinical severity in Parkinson's disease and correlates with PET. <i>Parkinsonism and Related Disorders</i> , 2001 , 7, 305-309	3.6	37
61	Daytime somnolence in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2001 , 7, 283-286	3.6	30
60	Positron emission tomography of dopamine pathways in familial Parkinsonian syndromes. <i>Parkinsonism and Related Disorders</i> , 2001 , 8, 51-6	3.6	8
59	Antisense strategies for the treatment of neurological disease. <i>Expert Opinion on Therapeutic Patents</i> , 2001 , 11, 547-562	6.8	
58	Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. <i>Annals of Neurology</i> , 2001 , 49, 298-303	9.4	49
57	In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. <i>Annals of Neurology</i> , 2000 , 47, 493-503	9.4	443
56	Dopamine transporter function assessed by antisense knockdown in the rat: protection from dopamine neurotoxicity. <i>Synapse</i> , 2000 , 37, 171-8	2.4	18
55	Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. <i>Journal of Neural Transmission</i> , 2000 , 107, 49-57	4.3	56
54	Effects of oligonucleotide antisense to dopamine D(1A) receptor messenger RNA in a rodent model of levodopa-induced dyskinesia. <i>Neuroscience</i> , 2000 , 98, 61-7	3.9	12
53	Dopamine D(1A) receptor function in a rodent model of tardive dyskinesia. <i>Neuroscience</i> , 2000 , 101, 629-35	3.9	24
52	Nigrostriatal dopamine system and motor lateralization. <i>Behavioural Brain Research</i> , 2000 , 112, 63-8	3.4	67
51	In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease 2000 , 47, 493		4
50	Unilateral pallidotomy for reduction of parkinsonian pain. <i>Journal of Neurosurgery</i> , 1999 , 91, 198-201	3.2	46
49	Etiology of Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 1999 , 26 Suppl 2, S5-12	1	22
48	Differential diagnosis of parkinsonism. <i>Canadian Journal of Neurological Sciences</i> , 1999 , 26 Suppl 2, S1-4	1	5
47	Age-dependent decline of dopamine D1 receptors in human brain: a PET study. <i>Synapse</i> , 1998 , 30, 56-61	2.4	175

46	Effect of age on caudate dopaminergic function in idiopathic Parkinsonism. <i>Parkinsonism and Related Disorders</i> , 1998 , 4, 1-5	3.6	4
45	Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [¹¹ C]-raclopride and positron-emission tomography. <i>Neurology</i> , 1998 , 50, 1028-32	6.5	64
44	Neuroreceptor imaging: new developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites). <i>Current Opinion in Neurology</i> , 1998 , 11, 327-33	7.1	10
43	A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. <i>NeuroReport</i> , 1997 , 8, 669-72	1.7	25
42	Pallidotomy for tardive dyskinesia. <i>Lancet, The</i> , 1997 , 349, 777-8	4.0	36
41	The neurotensin antagonist SR 48692 fails to modify the behavioural responses to a dopamine D1 receptor agonist in the rat. <i>Neuropharmacology</i> , 1997 , 36, 93-9	5.5	4
40	The effects of CCK-4 on dopamine D1 agonist-induced grooming are blocked by a CCK(A) receptor antagonist: evidence for a novel CCK receptor subtype?. <i>Neuropharmacology</i> , 1997 , 36, 1679-88	5.5	4
39	Effects of graft-derived dopaminergic innervation on the target neurons of patch and matrix compartments of the striatum. <i>Neuroscience</i> , 1997 , 76, 1173-85	3.9	5
38	Behavioural evidence for cholecystokinin-dopamine D1 receptor interactions in the rat. <i>European Journal of Pharmacology</i> , 1996 , 298, 7-15	5.3	8
37	Which dopamine receptor(s) do we need for motor function? Lessons from gene targeting and translational blockade. <i>Parkinsonism and Related Disorders</i> , 1996 , 2, 167-75	3.6	3
36	Effects of ethanol in a putative rodent model of tardive dyskinesia. <i>Pharmacology Biochemistry and Behavior</i> , 1996 , 54, 541-6	3.9	4
35	Effects of subthalamic nucleus lesions in a putative model of tardive dyskinesia in the rat. <i>Synapse</i> , 1996 , 24, 256-61	2.4	17
34	Pharmacological characterization of grooming induced by a selective NK-1 tachykinin receptor agonist. <i>Brain Research</i> , 1995 , 700, 115-20	3.7	13
33	Absence of mutations in superoxide dismutase and catalase genes in patients with Parkinson's disease. <i>Archives of Neurology</i> , 1995 , 52, 1160-3		31
32	Effects of neurotensin in a rodent model of tardive dyskinesia. <i>Neuropharmacology</i> , 1995 , 34, 457-62	5.5	21
31	Environmental exposures in elderly Canadians with Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 1995 , 22, 232-4	1	23
30	Localization of striatal and nigral tachykinin receptors in the rat. <i>Brain Research</i> , 1994 , 646, 13-8	3.7	46
29	Dopamine D1 receptor agonist-induced grooming is blocked by the opioid receptor antagonist naloxone. <i>European Journal of Pharmacology</i> , 1994 , 259, 301-3	5.3	14

28	The opiate antagonist naloxone suppresses a rodent model of tardive dyskinesia. <i>Movement Disorders</i> , 1993 , 8, 445-52	7	17
27	Neuroleptic-induced chewing movements in the rat are suppressed by peripherally but not centrally administered CCK and abolished by bilateral subdiaphragmatic vagotomy. <i>Neuropharmacology</i> , 1993 , 32, 555-60	5.5	4
26	Effects of ageing on tachykinin function in the basal ganglia. <i>Brain Research</i> , 1993 , 632, 21-8	3.7	13
25	Prevention and Management of Late Stage Complications in Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 1992 , 19, 113-116	1	7
24	Neurotensin and neurotensin analogues modify the effects of chronic neuroleptic administration in the rat. <i>Brain Research</i> , 1991 , 558, 289-95	3.7	15
23	Behavioural effects of selective tachykinin agonists in midbrain dopamine regions. <i>Brain Research</i> , 1991 , 565, 254-62	3.7	52
22	Autoradiographic visualization of NK-3 tachykinin binding sites in the rat brain, utilizing [3H]senktide. <i>Brain Research</i> , 1990 , 534, 1-7	3.7	72
21	Pharmacological characterization of the behavioural syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT. <i>Brain Research</i> , 1990 , 517, 111-6	3.7	39
20	Peptide-dopamine interactions in the central nervous system: implications for neuropsychiatric disorders. <i>Journal of Psychopharmacology</i> , 1989 , 3, 99-120	4.6	15
19	Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists. <i>Psychopharmacology</i> , 1989 , 98, 372-9	4.7	51
18	Effects of ageing on the behavioural responses to dopamine agonists: decreased yawning and locomotion, but increased stereotypy. <i>Brain Research</i> , 1989 , 495, 20-30	3.7	39
17	The NK-3 tachykinin agonist senktide elicits yawning and chewing mouth movements following subcutaneous administration in the rat. Evidence for cholinergic mediation. <i>Psychopharmacology</i> , 1988 , 95, 502-6	4.7	16
16	The NK-3 tachykinin receptor agonist senktide elicits 5-HT-mediated behaviour following central or peripheral administration in mice and rats. <i>British Journal of Pharmacology</i> , 1988 , 94, 285-7	8.6	58
15	Senktide, a selective neurokinin B-like agonist, elicits serotonin-mediated behaviour following intracisternal administration in the mouse. <i>Neuroscience Letters</i> , 1987 , 80, 321-6	3.3	33
14	Apomorphine-induced yawning in rats is abolished by bilateral 6-hydroxydopamine lesions of the substantia nigra. <i>Psychopharmacology</i> , 1987 , 93, 336-42	4.7	36
13	Controlling for cerebral atrophy in positron emission tomography data. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1987 , 7, 510-2	7.3	11
12	Cerebral metabolism of glucose in benign hereditary chorea. <i>Movement Disorders</i> , 1986 , 1, 33-44	7	36
11	Glucose use correlations: a matter of inference. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1986 , 6, 511-2	7.3	26

10	Regression model for predicting dissociations of regional cerebral glucose metabolism in individuals at risk for Huntington's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1986 , 6, 756-62	73	17
9	Double-blind study of botulinum toxin in spasmodic torticollis. <i>Lancet, The</i> , 1986 , 2, 245-7	40	539
8	Dementia in movement disorders. <i>Canadian Journal of Neurological Sciences</i> , 1986 , 13, 546-58	1	6
7	Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics. <i>Stroke</i> , 1985 , 16, 734-6	6.7	64
6	Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease. <i>Nature</i> , 1985 , 317, 246-8	50.4	270
5	Nemaline myopathy with associated cardiomyopathy. Report of clinical and detailed autopsy findings. <i>Archives of Neurology</i> , 1985 , 42, 1084-6		28
4	(+)-4-Propyl-9-hydroxynaphthoxazine (PHNO), a new dopaminomimetic, in treatment of parkinsonism. <i>Lancet, The</i> , 1985 , 2, 1330-1	40	30
3	Synthesis of thromboxane B2 and prostaglandins by bovine gastric mucosal microsomes. <i>Prostaglandins</i> , 1977 , 14, 819-27		38
2	Neuroimaging of Parkinson's disease and multiple system atrophy in patients with sleep disturbance	305-315	
1	Neuroimaging of Parkinson's disease	361-370	